{"id":"NCT00125164","sponsor":"Ipsen","briefTitle":"Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency","officialTitle":"Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Prepubertal Children With Growth Failure Associated With Primary IGF-1 Deficiency: A Phase 3, Randomized, Open Label, Observation-Controlled, Multicenter, Parallel-Dose Comparison Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-03","primaryCompletion":"2008-07","completion":"2008-07","firstPosted":"2005-07-29","resultsPosted":"2010-04-30","lastUpdate":"2019-09-18"},"enrollment":137,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Growth Disorders","Insulin-Like Growth Factor-1 Deficiency"],"interventions":[{"type":"DRUG","name":"rhIGF-1 (mecasermin, Tercica, Inc.)","otherNames":[]}],"arms":[{"label":"Untreated","type":"NO_INTERVENTION"},{"label":"40 μg/kg BID (twice daily dosing)","type":"EXPERIMENTAL"},{"label":"80 μg/kg BID (twice daily dosing)","type":"EXPERIMENTAL"},{"label":"120 μg/kg BID (twice daily dosing)","type":"EXPERIMENTAL"}],"summary":"This study is intended to determine whether twice daily weight based dosing with recombinant human insulin-like growth factor (rhIGF-1) will safely and effectively increase the growth of prepubertal children with short stature associated with low IGF-1 levels but who produce sufficient growth hormone (GH). Subjects will be randomized to either an observation arm or to active treatment.","primaryOutcome":{"measure":"Height Velocity During the First Year - Intent to Treat (ITT)Population","timeFrame":"Measured at baseline and at one year","effectByArm":[{"arm":"Untreated","deltaMin":5.2,"sd":1},{"arm":"80 μg/kg BID (Twice Daily Dosing)","deltaMin":6.9,"sd":1},{"arm":"120 μg/kg BID (Twice Daily Dosing)","deltaMin":7.7,"sd":1.5}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG003","p":"< 0.0001"},{"comp":"OG002 vs OG003","p":"0.0032"}]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":25},"commonTop":["Headache","Upper respiratory tract infection","Cough","Nasopharyngitis","Hypoglycemia"]}}